Silence Therapeutics (NASDAQ:SLN) Shares Down 4.5%

Silence Therapeutics plc (NASDAQ:SLN - Get Free Report)'s share price was down 4.5% on Tuesday . The company traded as low as $20.25 and last traded at $20.45. Approximately 21,758 shares changed hands during mid-day trading, a decline of 91% from the average daily volume of 240,996 shares. The stock had previously closed at $21.41.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on SLN shares. BMO Capital Markets initiated coverage on shares of Silence Therapeutics in a research report on Wednesday, January 31st. They issued an "outperform" rating and a $67.00 target price on the stock. HC Wainwright reiterated a "buy" rating and set a $75.00 price target on shares of Silence Therapeutics in a report on Friday, March 15th. Morgan Stanley lifted their price target on shares of Silence Therapeutics from $29.00 to $45.00 and gave the stock an "overweight" rating in a report on Thursday, March 14th. Finally, Chardan Capital lifted their price target on shares of Silence Therapeutics from $26.00 to $42.00 and gave the stock a "buy" rating in a report on Thursday, March 14th.

Silence Therapeutics Trading Down 1.9 %

The company has a quick ratio of 4.56, a current ratio of 4.56 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $628.53 million, a P/E ratio of -14.38 and a beta of 1.41. The firm's 50 day simple moving average is $22.99 and its two-hundred day simple moving average is $16.40.

Silence Therapeutics (NASDAQ:SLN - Get Free Report) last posted its earnings results on Wednesday, March 13th. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.22). The business had revenue of $2.61 million for the quarter, compared to the consensus estimate of $11.46 million. Silence Therapeutics had a negative return on equity of 262.17% and a negative net margin of 171.41%. As a group, analysts forecast that Silence Therapeutics plc will post -1.38 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Cantor Fitzgerald L. P. lifted its stake in shares of Silence Therapeutics by 1.6% during the 2nd quarter. Cantor Fitzgerald L. P. now owns 293,893 shares of the company's stock valued at $1,616,000 after buying an additional 4,735 shares in the last quarter. Lynx1 Capital Management LP bought a new stake in Silence Therapeutics during the 3rd quarter worth approximately $2,315,000. Schonfeld Strategic Advisors LLC bought a new stake in Silence Therapeutics during the 4th quarter worth approximately $450,000. Citadel Advisors LLC bought a new stake in Silence Therapeutics during the 4th quarter worth approximately $378,000. Finally, Millennium Management LLC increased its holdings in Silence Therapeutics by 19.8% during the 4th quarter. Millennium Management LLC now owns 17,436 shares of the company's stock worth $266,000 after acquiring an additional 2,879 shares during the period. 98.73% of the stock is currently owned by hedge funds and other institutional investors.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.